Pancreatic endocrine tumors (PETs) have long fascinated clinicians and investigators
despite their relative rarity. Their clinical presentation varies depending on whether the …

Pancreatic endocrine tumors (PETs) have long fascinated clini-cians, because some can
release biologically active hormones that cause distinct syndromes and provide important …

Purpose We investigated the global gene expression in a large panel of pancreatic
endocrine tumors (PETs) aimed at identifying new potential targets for therapy and …

Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are increasing in both
incidence and prevalence. A delay in correct diagnosis is common for these lesions. This …

The expression of the early response gene immediate early response 3 (IER3), formerly
known as IEX-1, is induced by a great variety of stimuli, such as growth factors, cytokines …

Background Cancers of the pancreas originate from both the endocrine and exocrine
elements of the organ, and represent a major cause of cancer-related death. This study …

Pancreatic neuroendocrine tumours (PETs) are the second most frequent pancreatic
neoplasms. Their poor chemosensitivity, high rate of metastatic disease and relatively long …

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) constitute a
heterogeneous group of tumours associated with variable clinical presentations, growth …

The intrinsic nature of tumour behaviour (stable vs progressive) and the presence of liver
metastases are key factors in determining the outcome of patients with a pancreatic …

Neuroendocrine tumors can develop either sporadically or in association with familial
syndromes such as multiple endocrine neoplasia type 1 (MEN1), multiple endocrine …